If you have a colleague to whom you would like to recommend this page, or if you just want to send yourself a reminder, here is an easy way to do it!
Simply fill in the e-mail address of the person(s) you wish to share this page with, add your name and e-mail address, and click the SEND button.
Janssen does not maintain or capture the contact information requested on the right in any way. Once you have sent this information, it is immediately deleted from our system.
INVEGA® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). The efficacy of INVEGA® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (12-17 years of age), as well as one maintenance trial in adults. INVEGA® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressant therapy in adults. The efficacy of INVEGA® in schizoaffective disorder was established in two 6-week trials in adults.